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64 ±. 22 for WTP £0,0. 81±0.16 for £ 1 to 49,. 81±15 for £ 50 to 99,. 76±. 16 for £100 to 
199,. 79± for £ 200 to 299,. 71±. 19 for £300 or more. Patients spent a mean of 50±134 
minutes (HDSS = 2), 65±119 minutes (HDSS = 3) and 161±293 minutes (HDSS = 4) for 
daily management of hyperhidrosis. WTP showed the lowest correlation to disease 
severity. ConClusions: The current study underscores the multidimensionality 
of the burden of hyperhidrosis, with all aspects showing greater impairment with 
greater disease severity. Health utility and daily time spent in managing the condi-
tion offered significant discrimination of patients.
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objeCtives: To assess psoriasis patients’ subjective expectations regarding their 
future health-related quality of life (HRQOL) and life-expectancy, and to explore 
variables associated with under- or overestimating behaviour. Methods: A cross-
sectional questionnaire survey of adult moderate to severe psoriasis patients was 
carried out. Patients were asked to indicate the age they expect themselves to live. 
HRQOL expectations were measured by the EQ-5D descriptive system for 6 months 
ahead and for future ages of 60,70,80 and 90, respectively. Current health state was 
evaluated with EQ-5D and visual analogue scale (EQ VAS), Dermatology Life Quality 
Index (DLQI) and Psoriasis Area and Severity Index (PASI). Results: Overall 167 
patients (71% males) were included in the analysis with mean age of 50.38±12.35 
years, mean EQ-5D, EQ VAS, DLQI and PASI scores were 0.71±0.30,65.3±21.08,5. 89±7.10 
and 7.82±10.13, respectively. Currently 56% of the patients were on biological therapy. 
Patients expected 0.1±0.23 mean improvement in EQ-5D scores within 6 months 
(p< 0.001); inverse or palmoplantar psoriasis, and using only topical treatment or 
initiation of the first biological at the time of the survey were likely associated with 
higher expectations. Males overestimated their life-expectancy by 2.94±11.86 years 
whereas females underestimated by 5.23±9.34 years (p< 0.001) compared to the gen-
der- and age-matched statistical life-expectancy. Expected mean EQ-5D scores for 
ages from 60 to 90 were: 0.56±0.48,0. 38±0.50,0. 15±0.55, and -0.17±0.54 (p< 0.001), 
respectively that are lower than the general population norms in Hungary. Both for 
6 months ahead and older ages, expected EQ-5D correlated moderately with current 
EQ-5D and EQ VAS and only weakly with DLQI and PASI (p< 0.05). ConClusions: 
Patients expected considerable improvement in their HRQOL for the near future and 
large-scale deterioration for older ages. Exploring unrealistic expectations might help 
to prevent dissatisfaction with treatment benefits and to improve compliance.
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objeCtives: The main objective of this study was to evaluate the process in which 
patients with single sided deafness proceed to receive bone conduction implants. 
Factors contributing to decisions for or against implantation were also com-
piled. Methods: Using a comprehensive search strategy, several online databases 
were searched to identify studies published since 2002. Research involving adults 
and children with single sided deafness (SSD); and reporting on patient preference 
for receiving BCIs were included. Screening of titles, and data extraction and quality 
assessment of full papers were undertaken by one reviewer with any uncertainties 
resolved by consultation with a second reviewer. Results: 16 studies were identi-
fied covering a total of 914 individuals diagnosed with SSD. All patients who trialled 
a CROS device preferred to receive a BCI. Acceptance of new generation CROS devices 
is suggested to be better but still low. Following a BCI Headband trial 19% to 77% of 
patients across studies (mean 51%) proceeded to receive a BCI. When reported, the 
most common reason for rejecting implantation was insufficient benefit with the 
Headband in speech in noise or insufficient/no relief from tinnitus. Studies assess-
ing factors in decision making found that age, gender, aetiology, duration of hearing 
loss or the presence of contralateral hearing loss did not differ between individu-
als who decide for or against implantation. One study so far suggests the role of 
transcranial attenuation at 2 kHz and tinnitus loudness to play a role in decision 
making. ConClusions: When given the option to trial traditional treatments and 
BCI simulators/Headbands many patients with SSD reject BCIs. This research high-
lights the importance of providing such trials before implantation. It is still unknown 
which aspects play a role in decision making and identifying better candidates.
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objeCtives: To synthesize and analyze the available information on the burden of 
chronic urticaria (CU) [Patients’ Reported Outcomes (PROs): Health related quality 
of life (HRQoL), adherence, satisfaction, preferences, use of medical resources and 
costs] in Europe. Methods: A systematic review on PROs and costs of CU was 
performed. International (Pub Med, WOK, Scopus, Cochrane Library) and national 
(CSIC-IME, IBECS, MEDES) databases were consulted. Original articles, narrative/sys-
tematic reviews of studies developed in Europe, until December 2013 were retrieved. 
Editorials, letters/commentaries, and efficacy or economic evaluations of specific 
drugs were excluded. Costs were updated to € , 2013. Results: 9 studies assessed 
HRQoL (3, Germany; 1, France, Greece, Italy, Spain, UK, Germany/France, respectively) 
and 1 satisfaction with treatments (Germany/France). No studies on adherence or 
preferences for treatments were identified. The CU-Q2oL instrument, (0-100, higher 
value, worse HRQoL), was the most frequently used (n= 4). Scores ranged from 18.4 
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objeCtives: Actinic keratosis (AK) is a common skin condition associated with 
cumulative sun exposure that may progress to non-melanoma skin cancer. The 
disease can potentially influence Health Related Quality of Life (HRQoL), but stud-
ies of HRQoL in patients with AK are limited. The objective was to analyze HRQoL 
in patients with AK using generic and disease-specific HRQoL instruments and to 
analyze the relationship between instruments. Methods: AK patients who vis-
ited dermatological clinics in Denmark were included in an observational, cross-
sectional, study in a multi-center setting. Dermatologists assessed AK severity 
and patients completed: Actinic Keratosis Quality of Life Questionnaire (AKQoL), 
Dermatology Life Quality Index (DLQI), EQ-5D (5L), and EuroQoL Visual Analogue 
Scale (EQ-VAS). Results: A total of 312 patients from 10 clinics were included in 
the analyses. In general, patients with AK reported impaired HRQoL. The mean 
values (possible range) were: AKQoL 6.7 (0-27), DLQI 2 (0-30), EQ-5D-5L 0.88 (0-1), 
and EQ-VAS 79 (0-100). HRQoL was least affected in patients with mild actinic dis-
ease, whereas patients with severe actinic damage suffered from further impaired 
HRQoL (mean AKQoL 10.1 and DLQI 4.6). The correlation between DLQI and AKQoL 
was moderate (0.52), whereas the correlations between DLQI and EQ-5D (-0.36) and 
between AKQoL and EQ-5D (-0.10) were weak. ConClusions: All patients with AK 
had impaired HRQoL. Patients with severe actinic damage were considerably more 
affected than those with mild disease. Correlations between instruments demon-
strate that they are complementary as they measure different aspects of HRQoL 
and are used for different purposes. EQ-5D is essential for economic evaluations, 
the DLQI is responsive to changes in relation to treatment and AKQoL captures 
important aspects related to sun damaged skin.
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objeCtives: Specific ranges of scores reflecting patient severity or changes in 
severity have not been established for average daily urticaria activity summed 
over 7 days (UAS7; range= 0-42), a common measure for assessing CSU disease 
activity. This study evaluates whether five non-overlapping health states derived 
from the continuous UAS7 score can discriminate between patients with different 
severities of urticaria and are reproducible across multiple studies. Methods: 
Data come from three randomised, double-blind, placebo-controlled Phase III 
clinical trials evaluating the effect of omalizumab on symptoms of patients with 
refractory CSU. Five CSU health states were defined: Urticaria-Free (UAS7= 0); Well-
Controlled Urticaria (UAS7= 1-6); Mild Urticaria (UAS7= 7-15); Moderate Urticaria 
(UAS7= 16-27); Severe Urticaria (UAS7= 28-42). Comparison variables included the 
Dermatology Life Quality Index (DLQI), a 10-item dermatologic QoL instrument 
(range= 0-30; higher scores= greater QoL impairment); patient diary questions ask-
ing about sleep and activity interference; presence of angioedema; and number 
of diphenhydramine 25mg pills taken in previous 24 hours. Analyses established 
whether different UAS7 health states showed different values on comparison 
variables. Analyses were replicated across the trials at baseline and weeks 12,24, 
and 40 (ASTERIA I and GLACIAL) and baseline and weeks 12 and 28 (ASTERIA II).  
Results: Mean values for comparison variables were lowest (zero or very 
close to zero) for patients who were Urticaria-Free and highest for those with 
Severe Urticaria. For Well-Controlled and Mild Urticaria comparison variable 
values increased. Larger increases in values occurred for Moderate and Severe 
Urticaria. Changes in categorical health state severity were highly related to cat-
egorical changes in DLQI (p< 0.001 for all trials and time points). ConClusions: 
Categorical UAS7 health states show meaningful differences in mean values on 
comparison variables and are highly related to established levels of effect on 
dermatological QoL. Categorical UAS7 health states could be informative about 
subgroups for economic models and useful for clinical practice.
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objeCtives: The objective of this study was to estimate the burden associated 
with primary hyperhidrosis by assessing patient’s health utilities, willingness 
to pay (WTP) for a complete cure and daily time spent in managing the condi-
tion. Methods: The data used in this study were collected under a longitudinal 
multi-stage research undertaken to develop and validate a new HRQoL instrument 
from patients with hyperhidrosis recruited through online social networking com-
munities (Hyperhidrosis support group UK and International hyperhidrosis society) 
from January to August 2013. Only the baseline assessment is used in this analy-
sis. Disease severity was measured using the Hyperhidrosis Disease Severity Scale 
(2 = for tolerable sweating, 3 = …barely tolerable sweating, 4 = intolerable sweating). 
The EuroQoL 5D-5L was used for assessing health utility index. Results: EQ-5D 
health utility index was lower in patients with more severe hyperhidrosis [mean 
utility value = . 85± 0.13 for HDSS = 2,0. 8±. 15 for HDSS = 3, and 0.69±. 2 for HDSS 
= 4, chi-square = 25.86, df = 2, p < 0.001]. Further, the health utility index was. 
